PRESENTATION

Q4 2025 — Presentation

Q4 2025PDF · 16 pages303 KB
Elevance Health
4Q 2025 Earnings Presentation
January 28, 2026

-- 1 of 16 --

2
Key Highlights
1 2025 Results Elevance Health fourth quarter operational results consistent with expectations
• 	4Q 2025 and full year adjusted diluted EPS 1 of $3.33 and $30.29, respectively
• 	4Q 2025 benefit expense ratio of 93.5% in line with guidance
• 	Cost trend development consistent with expectations across major lines of business
• 	4Q 2025 adjusted operating expense ratio of 10.8% included both actions to support and strengthen our
workforce and the partial pull-forward of investments planned for 2026
• 	2025 adjusted diluted EPS 1 includes ~$3.75 of non-recurring favorable items, primarily tax-related benefits
2 2026 Guidance &
2027 Outlook
2026 adjusted diluted EPS1 guidance of at least $25.50
• 	Operating revenue to decline in the low single digit percentage range
• 	Benefit expense ratio of 90.2% +/- 50 basis points
• 	Adjusted operating gain1 projected to be at least $6.8 billion
2027 adjusted diluted EPS1 to grow at least 12%, off our ending 2026 earnings baseline
3 Strategic Focus
Areas
2026 is a year of execution and repositioning: Prioritizing Medicare margin improvement, navigating near-
term Medicaid headwinds, and returning ACA to a more sustainable profile.
Focused strategy to improve affordability and experience: Scaling solutions to enhance outcomes and reduce
costs while bringing innovative, AI-enabled solutions to members and care providers.
Efforts underway to improve consistency of performance through pricing discipline, enhanced analytics to
anticipate cost trend, operational execution, targeted investments, and opportunistic capital deployment.
1. 	See “GAAP Reconciliation” on slides 13 and 14 herein.

-- 2 of 16 --

33
Key Highlights
• 	Elevance Health fourth quarter results
were consistent with our outlook
• 	Operating revenue of $197.6 billion in
2025 grew 13% on improved premium
yields in Health Benefits, contributions
from acquisitions, and growth in
Medicare Advantage membership,
partly offset by Medicaid member
attrition
• 	Benefit expense ratio of 90.0% for the
year increased 150 bps, primarily
reflected higher cost trends across all
major lines of business
• 	Adjusted operating expense ratio of
10.5% in 2025 improved due to
disciplined expense management,
while investing concurrently to support
and strengthen our workforce, scale
Carelon, and accelerate technology
adoption across the enterprise
• 	Operating cash flow was $4.3B, or 0.8
times GAAP net income
Fourth Quarter & Full Year 2025 Results
Elevance Health 	4Q 2025 	4Q 2024 	Change 	2025 	2024 	Change
Operating Revenue1 	$49.3B 	$45.0B 	9.6% 	$197.6B 	$175.2B 	12.8%
Benefit Expense Ratio 	93.5% 	92.4% 	110 bps 	90.0% 	88.5% 	150 bps
Adjusted Operating
Expense Ratio2 	10.8% 	10.3% 	50 bps 	10.5% 	10.6% 	(10) bps
Adjusted Operating
Gain1,2 	$0.4B 	$0.8B 	(55.4%) 	$7.5B 	$9.3B 	(20.0%)
Adjusted Operating
Margin 1,2 	0.8% 	1.9% 	(110) bps 	3.8% 	5.3% 	(150) bps
Net Investment Income 	$493M 	$527M 	(6.5%) 	$2.2B 	$2.1B 	7.0%
Adjusted Diluted EPS 2 	$3.33 	$3.23 	3.1% 	$30.29 	$33.04 	(8.3%)
Operating Cash Flow 	$0.1B 	$0.7B 	($0.6B) 	$4.3B 	$5.8B 	($1.5B)
1. 	See “Basis of Presentation” on slide 12 herein.
2. 	See “GAAP Reconciliation” on slides 13 and 14 herein.

-- 3 of 16 --

44
Elevance Health 	2026 Outlook 	2025 Actual
Premium Revenue 	Mid Single Digit Decline 	$164.6B
Product Revenue 	Mid Single Digit Growth 	$24.5B
Service Fees 	Mid Single Digit Growth 	$8.5B
Total Operating Revenue1 	Low Single Digit Decline 	$197.6B
Benefit Expense Ratio 	90.2% +/- 50 bps 	90.0%
Adjusted Operating Expense Ratio 2 	10.6% +/- 50 bps 	10.5%
Adjusted Operating Gain 1,2 	At least $6.8B 	$7.5B
Net Investment Income 	~$1.88B 	$2.19B
Interest Expense 	~$1.53B 	$1.40B
Adjusted Diluted EPS2 	At least $25.50 	$30.29
Operating Cash Flow 	At least $5.5B 	$4.3B
2026 Outlook
Key Highlights
• 	2026 guidance for adjusted diluted
earnings per share of at least $25.50
• 	Operating revenue outlook reflects a
low double digit decline in risk-based
membership, partly offset by higher
premium yields and growth in Carelon
• 	Benefit expense ratio expected to be
up 20 bps at the midpoint, reflecting
prudent view of cost trend
• 	Adjusted operating expense ratio
expected to be 10 bps above 2025
levels at the midpoint due to
incremental investments to scale
Carelon, grow our digital and AI-
enabled solutions, and simplify the
member experience
• 	Expect to earn approximately two-
thirds of our adjusted EPS in the first
half of 2026
1. 	See “Basis of Presentation” on slide 12 herein.
2. 	See “GAAP Reconciliation” on slides 13 and 14 herein.

-- 4 of 16 --

55
Key Highlights
• 	In Health Benefits, we navigated a
dynamic operating environment,
principally in Medicaid and ACA, while
Commercial Group and Medicare
performance was robust
• 	Operating revenue grew 11% driven by
higher premium yields, acquisitions,
and growth in Medicare membership,
offset by declines in Medicaid
membership
• 	Adjusted operating margin was
impacted by elevated cost trend in
Medicaid and shifting member acuity
in ACA
• 	Guidance for operating revenue
growth reflects expected risk-based
membership attrition offset by higher
premium yields
• 	Operating margin expectations reflect
continued pressure in Medicaid, partly
offset by improved Medicare
performance
Health Benefits 	4Q 2025 	4Q 2024 	Change 	2025 	2024 	Change
Operating Revenue1 	$41.8B 	$37.6B 	11.3% 	$167.1B 	$150.3B 	11.2%
Adjusted Operating Gain1,2 	($0.2B) 	$0.2B 	NM 3 	$4.2B 	$6.3B 	(34.1%)
Adjusted Operating Margin 1,2 	(0.5%) 	0.6% 	(110) bps 	2.5% 	4.2% 	(170) bps
Membership 	45.2M 	45.7M 	(1.1%)
1. 	See “Basis of Presentation” on slide 12 herein.
2. 	See “Reportable Segment & Health Benefits Revenue Details” on slide 15 herein.
3. 	“NM” = calculation not meaningful.
Health Benefits
2025 Results | 2026 Outlook
Guidance 	2026 Outlook
Operating Revenue Growth 	Low Single Digit Decline
GAAP Operating Margin 	(50) – (25) basis points over 2025
Fee-Based Membership 	27.2M – 27.5M
Risk-Based Membership 	16.0M – 16.4M
Total Membership 	43.2M – 43.9M

-- 5 of 16 --

66
Key Highlights
• 	We are growing Carelon’s capabilities
to improve outcomes and reduce costs
• 	Carelon remains well positioned in
2026, expanding its solutions and
enhancing external relationships, even
as it navigates membership headwinds
• 	CarelonRx fourth quarter operating
revenue reflects robust script growth;
operating margin ended in line with our
revised expectations
• 	Carelon Services results were driven by
the expansion of risk-based solutions
and the acquisition of CareBridge
2025 Results | 2026 Outlook
Carelon 	4Q 2025 	4Q 2024 	Change 	2025 	2024 	Change
Operating Revenue1 	$18.7B 	$14.7B 	26.5% 	$71.7B 	$53.9B 	33.0%
Adjusted Operating Gain1,2 	$612M 	$642M 	(4.7%) 	$3.4B 	$3.1B 	10.1%
Adjusted Operating Margin 1,2 	3.3% 	4.4% 	(110) bps 	4.8% 	5.8% 	(100) bps
Adjusted Scripts 	88.5M 	82.9M 	6.8% 	340.7M 	318.4M 	7.0%
Consumers Served 	91.8M 	101.1M 	(9.2%)
1. 	See “Basis of Presentation” on slide 12 herein.
2. 	See “Reportable Segment & Health Benefits Revenue Details” on slide 15 herein.
Guidance 	2026 Outlook
CarelonRx Operating Revenue Growth 	Low Single Digit Growth
CarelonRx GAAP Operating Margin 	(25) – 0 basis points over 2025
Carelon Services Operating Revenue Growth 	Low Single Digit Growth
Carelon Services GAAP Operating Margin 	0 – 25 basis points over 2025
Health Services

-- 6 of 16 --

77
Elevance Health is a Lifetime, Trusted Health Partner
Lowering the cost of healthcare
We anticipate health trends early, give
caregivers the tools they need, and
make care easier to afford.
Making healthcare simple
We make accessing and using healthcare easy,
cutting red tape and simplifying systems and
processes so providers can provide care, and
members can live their healthiest lives.
To deliver on our mission of improving lives and communities and simplifying healthcare
WHAT
HOW
WHY
A lifetime, trusted health partner
committed to making healthcare better…
better costs, better experience, better
outcomes – for your whole health.

-- 7 of 16 --

88
Flywheel Supports Our Long-Term Growth Algorithm
Health Benefits
Optimize
the Core
Invest in
Growth
Accelerate
Targeting at least 12% average annual growth in
Adjusted Diluted Earnings Per Share
Over 45M medical members balanced
across commercial, Medicaid, Medicare,
and the Federal Employee Program,
leveraging the assets and capabilities
of Carelon to accelerate growth
As an integrated portfolio of whole
health solutions serving approximately
92M consumers, Carelon connects care
across physical, behavioral, social,
home health, and pharmacy needs to
bend the cost curve, enhance consumer
experiences, and deliver whole health,
affordably
Health Services

-- 8 of 16 --

99
Adjusted Operating Gain – High Single Digit to Low Double Digit CAGR 1
Long-Term Growth Algorithm
Revenue Growth
High Single Digit CAGR 1
Adjusted Operating Margin
Expanding to 5.0% – 6.0%
Capital Deployment
Approximately 4% Contribution to
Adjusted Diluted EPS CAGR 1
Health Benefits
Mid to High Single Digit CAGR
Driven by targeted membership growth, strategic
geographic and product expansion, and growth in
specialized populations
Carelon Services
High Teens to Low Twenties CAGR
Driven by risk-based revenue growth and M&A
CarelonRx
Low Double Digit CAGR
Driven by new client relationships and scaling of
specialty pharmacy capabilities
Strengthen operational
discipline to accelerate margin
normalization
Advance value-based care
models to improve outcomes
and reduce costs
Integrate technology to simplify
the experience for members and
care providers
Share Repurchases
Organic Reinvestment
Programmatic M&A targeting
integrated solutions that
strengthen health plan
competitiveness
+ 	+
1. 	CAGR = Compound Annual Growth Rate Target.
Reaffirming at least 12% average annual growth in Adjusted Diluted EPS, while recalibrating margin targets for the enterprise

-- 9 of 16 --

10	10
Committed to Strong Growth Over the Long-Term
M&A/ Organic
Reinvestment
50%
Share
Repurchase
30%
Dividends
20%
3.8%
5.0% – 6.0%
2025 	Target
$198B
High Single
Digit CAGR1
2025 	Target
Elevance Health
4.8%
Mid Single
Digit
2025 	Target
$72B
Mid Teens
CAGR1
2025 	Target
Carelon 2
2.5%
Mid Single
Digit
2025 	Target
$167B
Mid to High
Single Digit
CAGR1
2025 	Target
Health Benefits
Capital
Allocation
Targeting at least 12% average annual
growth in Adjusted Diluted EPS
Adjusted3
Operating
Margin
Revenue
(in billions)
1. 	CAGR = Compound Annual Growth Rate Target.
2. 	The CAGR target for revenue and the operating margin target for Carelon includes: (i) a low double digit revenue CAGR and mid single digit percentage operating margin for
CarelonRx, and (ii) a high teens to low twenties revenue CAGR and mid to high single digit percentage operating margin for Carelon Services.
3. 	See “GAAP Reconciliation” on slides 13 and 14 herein.
Recalibrating segment margin targets for our current portfolio and our strategic trajectory

-- 10 of 16 --

11
Forward-Looking Statements
This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect our views
about future events and financial performance and are generally not historical facts. Words such as “expect,” “feel,” “believe,” “will,” “may,” “should,” “anticipate,” “intend,” “estimate,”
“project,” “forecast,” “plan,” “potential,” “predict” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to:
financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and
services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond
our control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. You are cautioned not to place
undue reliance on these forward-looking statements that speak only as of the date hereof. You are also urged to carefully review and consider the various risks and other
disclosures discussed in our reports filed with the U.S. Securities and Exchange Commission from time to time, which attempt to advise interested parties of the factors that affect
our business. Except to the extent required by law, we do not update or revise any forward-looking statements to reflect events or circumstances occurring after the date hereof.
These risks and uncertainties include, but are not limited to: trends in healthcare costs and utilization rates; reduced enrollment; our ability to secure and implement sufficient
premium rates; the impact of large scale medical emergencies, such as public health epidemics and pandemics, and other catastrophes; the impact of new or changes in existing
federal, state and international laws or regulations, including laws and regulations impacting healthcare, insurance, pharmacy services and other diversified products and services,
or their enforcement or application; the impact of cyber-attacks or other privacy or data security incidents or our failure to comply with any privacy, data or security laws or
regulations, including any investigations, claims or litigation related thereto; failure to effectively maintain and modernize our information systems, or failure of our information
systems or technology, including artificial intelligence, to operate as intended; failure to effectively maintain the availability and integrity of our data; changes in economic and
market conditions, as well as regulations that may negatively affect our liquidity and investment portfolios; competitive pressures and our ability to adapt to changes in the industry
and develop and implement strategic growth opportunities; risks and uncertainties regarding Medicare and Medicaid programs, including those related to non-compliance with
the complex regulations imposed thereon; our ability to maintain and achieve improvement in Centers for Medicare and Medicaid Services Star Ratings and other quality scores
and funding risks with respect to revenue received from participation therein; a negative change in our healthcare product mix; costs and other liabilities associated with litigation,
government investigations, audits or reviews; our ability to contract with providers on cost-effective and competitive terms; risks associated with providing healthcare, pharmacy
and other diversified products and services, including medical malpractice or professional liability claims and non-compliance by any party with the pharmacy services agreement
between us and CaremarkPCS Health, L.L.C.; the effects of any negative publicity or sentiment related to the health benefits industry in general or us in particular; risks associated
with mergers, acquisitions, joint ventures and strategic alliances; possible impairment of the value of our intangible assets if future results do not adequately support goodwill and
other intangible assets; possible restrictions in the payment of dividends from our subsidiaries and increases in required minimum levels of capital; our ability to repurchase shares
of our common stock and pay dividends on our common stock due to the adequacy of our cash flow and earnings and other considerations; the potential negative effect from our
substantial amount of outstanding indebtedness and the risk that increased interest rates or market volatility could impact our access to or further increase the cost of financing; a
downgrade in our financial strength ratings; events that may negatively affect our licenses with the Blue Cross and Blue Shield Association; intense competition to attract and retain
employees; risks associated with our international operations; and various laws and provisions in our governing documents that may prevent or discourage takeovers and business
combinations.

-- 11 of 16 --

12
Non-GAAP Measures and Basis of Presentation
This document references non-GAAP measures. These non-GAAP measures are intended to aid investors when comparing Elevance Health’s financial results among periods and
are not intended to be alternatives to any measure calculated in accordance with GAAP. Reconciliations of these non-GAAP measures to the most directly comparable measures
calculated in accordance with GAAP are available on Slides 13-14 of this document.
Operating revenue and operating gain/loss are the key measures used by management to evaluate performance in each of its reporting segments, allocate resources, set
incentive compensation targets and to forecast future operating performance. Operating gain/loss is calculated as total operating revenue less benefit expense, cost of
products sold and operating expense. It does not include net investment income, net gains/losses on financial instruments, interest expense, amortization of other intangible
assets and gains/losses on extinguishment of debt or income taxes, as these items are managed in a corporate shared service environment and are not the responsibility of
operating segment management. Operating Margin is defined as operating gain divided by operating revenue. Each of these measures is provided to further aid investors in
understanding and analyzing Elevance Health’s operating and financial results.

-- 12 of 16 --

13	13
Elevance Health GAAP Reconciliation — Shareholders’ Net Income
and Shareholders’ Earnings Per Diluted Share
Three Months Ended Dec 31 	Twelve Months Ended Dec 31
(In millions, except per share data) 	2025 	2024 	Change 	2025 	2024 	Change
Shareholders' net income 	$547 	$418 	30.9% 	$5,662 	$5,980 	(5.3%)
Add / (Subtract):
Amortization of other intangible assets 	164 	180 	628 	580
Net losses on financial instruments 	57 	74 	653 	445
Transaction and integration related costs1 	54 	66 	236 	224
Business dispositions and related items2 	41 	90 	41 	281
Litigation and settlement expenses1 	5 	12 	24 	692
Gain on sale of business 	— 	— 	— 	(201)
Business optimization charges1 	(34) 	— 	(38) 	268
Tax impact of non-GAAP adjustments 	(95) 	(93) 	(402) 	(575)
Net adjustment items 	192 	329 	1,142 	1,714
Adjusted shareholders' net income 	$739 	$747 	(1.1%) 	$6,804 	$7,694 	(11.6%)
Shareholders’ earnings per diluted share 	$2.47 	$1.81 	36.5% 	$25.21 	$25.68 	(1.8%)
Add / (Subtract):
Amortization of other intangible assets 	0.74 	0.78 	2.80 	2.49
Net losses on financial instruments 	0.26 	0.32 	2.91 	1.91
Transaction and integration related costs1 	0.24 	0.29 	1.05 	0.96
Business dispositions and related items2 	0.18 	0.39 	0.18 	1.21
Litigation and settlement expenses1 	0.02 	0.05 	0.11 	2.97
Gain on sale of business 	— 	— 	— 	(0.86)
Business optimization charges1 	(0.15) 	— 	(0.17) 	1.15
Tax impact of non-GAAP adjustments 	(0.43) 	(0.40) 	(1.79) 	(2..47)
Net adjustment items 	0.86 	1.42 	5.08 	7.36
Adjusted shareholders’ earnings per diluted share 	$3.33 	$3.23 	3.1% 	$30.29 	$33.04 	(8.3%)
Three Months Ended Dec 31 	Twelve Months Ended Dec 31
(In millions) 	2025 	2024 	Change 	2025 	2024 	Change
Income before income tax expense 	$215 	$606 	(64.5%) 	$6,710 	$7,904 	(15.1%)
Net investment income 	(493) 	(527) 	(2,194) 	(2,051)
Gain on sale of business 	— 	— 	— 	(201)
Net losses on financial instruments 	57 	74 	653 	445
Interest expense 	366 	340 	1,402 	1,185
Amortization of other intangible assets 	164 	180 	628 	580
Reportable segments operating gain 	$309 	$673 	(54.1%) 	$7,199 	$7,862 	(8.4%)
1. 	Adjustment item resides in the Corporate & Other reportable segment.
2. 	Adjustment item resides in the Health Benefits, CarelonRx, Carelon Services, and Corporate & Other reportable segments.
3. 	Totals may not foot due to rounding.

-- 13 of 16 --

14	14
Elevance Health GAAP Reconciliation — Operating Gain, Operating
Expense Ratio, and 2026 Outlook
Three Months Ended Dec 31 	Twelve Months Ended Dec 31
(In millions) 	2025 	2024 	Change 	2025 	2024 	Change
Operating expense 	$5,415 	$4,804 	12.7% 	$20,984 	$20,025 	4.8%
Add / (Subtract):
Transaction and integration related costs1 	(54) 	(66) 	(236) 	(224)
Business dispositions and related items2 	(41) 	(90) 	(41) 	(281)
Litigation and settlement expenses1 	(5) 	(12) 	(24) 	(692)
Business optimization charges1 	34 	— 	38 	(268)
Net adjustment items 	(66) 	(168) 	(263) 	(1,465)
Adjusted operating expense 	$5,349 	$4,636 	15.4% 	$20,721 	$18,560 	11.6%
Operating revenue 	$49,311 	$44,989 	9.6% 	$197,584 	$175,204 	12.8%
Operating expense ratio 	11.0% 	10.7% 	30 bp 	10.6% 	11.4% 	(80) bp
Adjusted operating expense ratio 	10.8% 	10.3% 	50 bp 	10.5% 	10.6% 	(10) bp
Three Months Ended Dec 31 	Twelve Months Ended Dec 31
(In millions) 	2025 	2024 	Change 	2025 	2024 	Change
Reportable segments operating gain 	$309 	$673 	(54.1%) 	$7,199 	$7,862 	(8.4%)
Add / (Subtract):
Transaction and integration related costs1 	54 	66 	236 	224
Business dispositions and related items2 	41 	90 	41 	281
Litigation and settlement expenses1 	5 	12 	24 	692
Business optimization charges1 	(34) 	— 	(38) 	268
Net adjustment Items 	66 	168 	263 	1,465
Reportable segments adjusted operating gain 	$375 	$841 	(55.4%) 	$7,462 	$9,327 	(20.0%)
Full Year 2026
Outlook
Shareholders’ earnings per diluted share 	At least $22.30
Add / (Subtract):
Amortization of other intangible assets3 	$2.00
Net losses on financial instruments3 	$1.15
Transaction and integration related costs1, 3 	$0.90
Litigation and settlement expenses1, 3 	$0.10
Tax impact of non-GAAP adjustments3 	Approximately ($0.95)
Net adjustment items 	$3.20
Adjusted shareholders’ earnings per diluted share 	At least $25.50
1. 	Adjustment item resides in the Corporate & Other reportable segment.
2. 	Adjustment item resides in the Health Benefits, CarelonRx, Carelon Services, and Corporate & Other reportable segments.
3. 	Adjustment item represents the midpoint of a projected range and serves as the estimated full year adjustment amount.

-- 14 of 16 --

15	15
Elevance Health
Reportable Segment & Health Benefits Revenue Details
Three Months Ended Dec 31 	Twelve Months Ended Dec 31
(In millions, Unaudited) 	2025 	2024 	Change 	2025 	2024 	Change
Operating Revenue
Health Benefits 	$41,835 	$37,580 	11.3% 	$167,094 	$150,275 	11.2%
CarelonRx 	11,644 	9,977 	16.7% 	43,400 	35,961 	20.7%
Carelon Services 	7,015 	4,769 	47.1% 	28,316 	17,961 	57.7%
Corporate & Other 	(83) 	(14) 	NM 6 	463 	309 	49.8%
Eliminations 	(11,100) 	(7,323) 	NM6 	(41,689) 	(29,302) 	NM6
Total Operating Revenue1 	$49,311 	$44,989 	9.6% 	$197,584 	$175,204 	12.8%
Operating Gain (Loss)
Health Benefits2 	($220) 	$207 	NM6 	$4,158 	$6,243 	(33.4%)
CarelonRx3 	724 	533 	(35.8%) 	2,418 	2,172 	11.3%
Carelon Services2,3 	(150) 	35 	NM6 	960 	717 	33.9%
Corporate & Other 2,3 	(45) 	(102) 	NM6 	(337) 	(1,270) 	NM6
Total Operating Gain1,4 	$309 	$673 	(54.1%) 	$7,199 	$7,862 	(8.4%)
Operating Margin
Health Benefits 	(0.5%) 	0.6% 	(110) bp 	2.5% 	4.2% 	(170) bp
CarelonRx 	6.2% 	5.3% 	90 bp 	5.6% 	6.0% 	(40) bp
Carelon Services 	(2.1%) 	0.7% 	(280) bp 	3.4% 	4.0% 	(60) bp
Total Operating Margin1 	0.6% 	1.5% 	(90) bp 	3.6% 	4.5% 	(90) bp
1. 	See “Basis of Presentation” on slide 12 herein.
2. 	Operating Gain for the three and twelve months ended December 31, 2024 included $90 and $281 million, respectively, of 2024 business dispositions and related items; including $74 and $215 million, respectively, for the Carelon Services segment; and $16 and $66 million, respectively, for the Health
Benefits segment. Operating Gain for the three and twelve months ended December 31, 2024 included $66 and $224 million, respectively, of transaction and integration related costs, $12 and $692 million, respectively, of litigation and settlement expenses, and $0 and $268 million, respectively, of
business optimization charges, all of which reside in the Corporate & Other reportable segment.
3. 	Operating Gain for the three and twelve months ended December 31, 2025 included $41 million of 2025 business dispositions and related items; including $45 million for the CarelonRx segment; ($7) million for the Carelon Services segment; and $3 million for the Corporate & Other segment.
Operating Gain for the three and twelve months ended December 31, 2025 included $54 and $236 million, respectively, of transaction and integration related costs, $5 and $24 million, respectively, of litigation and settlement expenses, and ($34) and ($38) million, respectively, of business
optimization charges, all of which reside in the Corporate & Other reportable segment.
4. 	Operating Gain for the three and twelve months ended December 31, 2025, and December 31, 2024 included items excluded from adjusted shareholders' net income. See "GAAP Reconciliation" on pages 13 and 14 herein.
5. 	The Individual business, including ACA products, is reported as part of Commercial Operating Revenue.
6. 	"NM" = calculation not meaningful.
Elevance Health has four reportable segments: Health Benefits (comprised of Individual, Employer Group risk-based, Employer Group fee-based, BlueCard®, Medicare, Medicaid, and Federal Employee Program
businesses); CarelonRx; Carelon Services; and Corporate & Other (comprised of businesses that do not individually meet the quantitative thresholds for an operating division as well as corporate expenses not
allocated to our other reportable segments).
Three Months Ended Dec 31 	Twelve Months Ended Dec 31
(In millions, Unaudited) 	2025 	2024 	Change 	2025 	2024 	Change
Health Benefits Operating Revenue
Commercial 	$12,747 	$11,851 	7.6% 	$50,401 	$46,816 	7.7%
Individual5 	2,248 	2,117 	6.2% 	9,295 	8,295 	12.1%
Medicare 	10,762 	9,054 	18.9% 	44,752 	36,795 	21.6%
Medicaid 	14,500 	12,755 	13.7% 	56,620 	51,937 	9.0%
Federal Employee Program 	3,826 	3,920 	(2.4%) 	15,321 	14,727 	4.0%
Total Health Benefits Operating Revenue1 	$41,835 	$37,580 	11.3% 	$167,094 	$150,275 	11.2%

-- 15 of 16 --



-- 16 of 16 --